Economic evaluations of novel antipsychotic medications: a literature review

Hudson, Teresa J.; Sullivan, Greer; Feng, Weiwei; Owen, Richard R.; Thrush, Carol R.

doi:10.1016/s0920-9964(02)00228-1

Cited by 18 publications

(11 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results of cost-effectiveness studies in younger patients with psychotic disorders have been mixed (Hudson et al, 2003). Data are needed regarding the comparative efficacy and cost-effectiveness data of the atypical antipsychotics over the traditional agents in older adults, and direct comparisons are needed of the cost-effectiveness of the individual atypical antipsychotics.…”

Section: Discussionmentioning

confidence: 99%

Antipsychotic use in the elderly: shifting trends and increasing costs

Rapoport

Mamdani

Shulman

et al. 2005

Int. J. Geriat. Psychiatry

View full text Add to dashboard Cite

The modest increase in antipsychotic prevalence in the elderly over the last ten years has been associated with a substantial increase in cost, with a significant shift towards use of the atypical antipsychotics. As the atypical antipsychotics are increasingly used for patients with dementia, which is becoming more prevalent in the aging population, an understanding of the benefits of these medications must be balanced with a detailed understanding of the material and financial implications.

show abstract

Section: Discussionmentioning

confidence: 99%

Antipsychotic use in the elderly: shifting trends and increasing costs

Rapoport

Mamdani

Shulman

et al. 2005

Int. J. Geriat. Psychiatry

View full text Add to dashboard Cite

show abstract

“…The findings from these studies are mixed, with some suggesting that the drugs reduce expenditures (Glazer and Johnstone, 1997) and others finding the opposite (Coley et al, 1999). As a recent review article notes (Hudson et al, 2003) the findings from most of the previous studies are not conclusive because of small sample sizes, short time periods, imputed data, or other design limitations. An even larger body of research has examined the effect of secondgeneration antipsychotics on the prevalence of adverse side effects, including extrapyramidal symptoms, diabetes, abnormal weight gain, and hyperlipidemia (Gianfrancesco et al, 2002;Koro, 2002;Leucht et al, 1999;Lund et al, 2001;Meyer, 2001;Sernyak et al, 2002).…”

Section: Previous Researchmentioning

confidence: 97%

Do new prescription drugs pay for themselves?

Duggan

2005

Journal of Health Economics

106

View full text Add to dashboard Cite

“…By reducing side-effects, for example, atypical antipsychotics may reduce non-adherence to medication, which significantly increases the probability of relapse into an acute schizophrenic episode (Weiden & Olfson, 1995), and in turn pushes up treatment and support costs (Almond, Knapp, Francois, Toumi, & Brugha, 2004). Thus, support for prescribing of atypical antipsychotics, relative to typical antipsychotics, in treating patients with schizophrenia, has also been made on cost-effectiveness grounds (Davis, Chen, & Glick, 2003;Hudson, Sullivan, Feng, Owen, & Thrush, 2003), although the evidence is not unequivocal (Basu, 2004;Duggan, 2005).…”

Section: Introductionmentioning

confidence: 99%